UroGen Pharma draws $25M second tranche from $100M BioPharma Credit facility

UroGen Pharma Ltd.

$25M Tranche B Loan requested Oct 21, 2022; funding expected Dec 16, 2022.
Interest rate: 8.25% + 3-month LIBOR (floor 1.25%); matures March 2027.
Proceeds to be used for general corporate and working capital requirements.
Repayment in four equal quarterly payments starting after 17th quarter anniversary of Tranche A closing.
Prepayment premiums: 3% if before 3rd anniversary, 2% if 3-4 yrs, 1% if after 4 yrs; makewhole within 2 yrs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.